Skip to main content

Table 4 Association of clinical, pathological and genotypic parameters with progression free survival (PFS).

From: A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

Parameters

n

Events

%PFS

p

Tumor size

    

   T2

76

12

62.6

0.089

   T3-T4

19

6

59.3

 

Lymph node involvement

    

   N0

76

10

57.31

0.0011

   N1-N2

19

8

44.7

 

Stage

    

   IIa

65

8

58.2

0.0232

   IIb

20

6

65.1

 

   IIIa-IIIb

10

4

42.3

 

RR4M

    

   Responders

35

1

96.7

0.0033

   Non-responders

60

17

45.6

 

rs10046

    

   GG

18

3

80.0

0.967

   AG/AA

80

15

81.3

 

rs4646

    

   CC

57

7

85.7

0.0686

   AC/AA

38

11

50.9